Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis.
Anderson, Craig S
Bertens, Anne Suzanne
van Boxtel, Martin
Carlson, Michelle C
Dixon, Roger A
van Gool, Willem A
Hever, Ann M
Hogan, David B
McFall, G Peggy
van Middelaar, Tessa
Moll van Charante, Eric P
Sachdev, Perminder S
Stephan, Blossom CM
Lippincott Williams & Wilkins Ltd.
MetadataShow full item record
Peters, R., Yasar, S., Anderson, C. S., Andrews, S., Antikainen, R., Arima, H., Beckett, N., et al. (2020). Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis.. Neurology, 94 (3), e267-e281. https://doi.org/10.1212/wnl.0000000000008732
Objective High blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting evidence regarding the best antihypertensive class for optimising cognition. Our objective was to determine whether any particular class of antihypertensive was associated with a reduced risk of cognitive decline or dementia using comprehensive meta-analysis including reanalysis of original participant data. Methods To identify suitable studies MEDLINE, Embase and PsycINFO® and pre-existing study consortia were searched from inception to December 2017. Authors of prospective longitudinal human studies or trials of antihypertensives were contacted for data-sharing and collaboration. Outcome measures were incident dementia or incident cognitive decline (classified using the reliable change index method). Data were separated into mid and late-life (>65 years) and each antihypertensive class was compared to no treatment and to treatment with other antihypertensives. Meta-analysis was used to synthesize data. Results Over 50,000 participants from 27 studies were included. Among those aged >65 years, with the exception of diuretics, we found no relationship by class with incident cognitive decline or dementia. Diuretic use was suggestive of benefit in some analyses but results were not consistent across follow-up time, comparator group and outcome. Limited data precluded meaningful analyses in those ≤65 years. Conclusions Our findings, drawn from the current evidence base, support clinical freedom in the selection of antihypertensive regimens to achieve blood pressure goals.
Humans, Dementia, Hypertension, Antihypertensive Agents, Aged, Aged, 80 and over, Middle Aged, Female, Male, Cognitive Dysfunction
No funding was received specifically for this project. The lead author is funded by the Australian National Health and Medical Research Council, National Institute for Dementia Research, Dementia Centre for Research Collaboration (NHMRC NNIDR DCRC). Other authors are funded from various sources.
Embargo Lift Date
External DOI: https://doi.org/10.1212/wnl.0000000000008732
This record's URL: https://www.repository.cam.ac.uk/handle/1810/296355